APA (7th ed.) Citation

AS, F., LM, M., DGS, P., SW, A., IA, H., PM, H., . . . M, M. (2024). Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology, 102(5), e208061. https://doi.org/10.1212/WNL.0000000000208061

Chicago Style (17th ed.) Citation

AS, Fleisher, et al. "Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease." Neurology 102, no. 5 (2024): e208061. https://doi.org/10.1212/WNL.0000000000208061.

MLA (9th ed.) Citation

AS, Fleisher, et al. "Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease." Neurology, vol. 102, no. 5, 2024, p. e208061, https://doi.org/10.1212/WNL.0000000000208061.